Spinal Muscular Atrophy Clinical Trial Pipeline Expands as 18+ Companies Advance 20+ Pipeline Therapies, Finds DelveInsight | Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics and Others

DelveInsight's "Spinal Muscular Atrophy (SMA) - Pipeline Insight, 2026" report provides comprehensive insights into 18+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. The report covers pipeline drug profiles across clinical and nonclinical stages, therapeutic assessment by product type, stage, route of administration, and molecule type, and also highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Spinal Muscular Atrophy treatment landscape. Learn more about the evolving Spinal Muscular Atrophy pipeline @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Spinal Muscular Atrophy Pipeline Report

• In 2026, the Spinal Muscular Atrophy pipeline landscape includes 18+ companies developing 20+ pipeline therapies for SMA treatment.
• The most advanced pipeline candidate identified in the report is from Scholar Rock, with its SMA therapy in Phase III development.
• The report covers products across Phase III, Phase II, Phase I, preclinical, discovery, and inactive/discontinued stages.
• The therapeutic landscape is assessed by route of administration, including oral, parenteral, intravenous, subcutaneous, and topical routes.
• The report also categorizes products by molecule type, including monoclonal antibody, peptides, polymer, small molecule, and gene therapy.
• The companies highlighted in the report include Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, and Amniotics.

Download for the full report for updates and the latest revolution in Spinal Muscular Atrophy care @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Spinal Muscular Atrophy Understanding

Spinal Muscular Atrophy (SMA) is a genetic disease that affects the central nervous system, peripheral nervous system, and voluntary skeletal muscle movement. The condition involves the loss of motor neurons in the spinal cord, and the common chromosome 5 form is classified into types 1 through 4 based on age of onset and severity.

The report also notes that SMA is a motor neuron disease with wide variability in age of onset, symptoms, and progression rate. Earlier onset generally corresponds to greater motor impairment, while later-onset forms are associated with higher levels of motor function.

The report provides a detailed picture of the Spinal Muscular Atrophy pipeline landscape, including the disease overview, treatment guidelines, commercial assessment, and clinical assessment of pipeline products under development. It also includes product descriptions covering mechanism of action, clinical studies, NDA approvals if any, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, and designations.

Spinal Muscular Atrophy Emerging Drugs Profile

• Apitegromab: Scholar Rock

Apitegromab is a selective inhibitor of myostatin activation and is being studied as an investigational candidate for SMA. Scholar Rock states that inhibiting myostatin activation may lead to a clinically meaningful improvement in motor function in patients with SMA. The report notes that the candidate has received multiple regulatory designations and is currently in Phase III development.

• ACTX-401: Alcyone Therapeutics

ACTX-401 is an AAV9-delivered gene replacement therapy designed to restore functional IGHMBP2 expression in patients with SMARD1 and CMT2S, which are IGHMBP2-related disorders. The therapy is currently under Phase I/II investigation for spinal muscular atrophy.

For more information on the Spinal Muscular Atrophy Emerging Drugs Profile, download DelveInsight's comprehensive Spinal Muscular Atrophy Pipeline Insight report @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Spinal Muscular Atrophy Pipeline Report Provides

• Detailed insights into companies developing therapies for SMA, with aggregate therapies developed by each company.
• Segmentation of therapeutic candidates into early-stage, mid-stage, and late-stage development for SMA treatment.
• Information on companies engaged in targeted therapeutics development, including active and inactive projects.
• Analysis of drugs under development by stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations, acquisition and merger activity, licensing, and therapeutic assessment of emerging SMA drugs.

Learn more about Spinal Muscular Atrophy drug opportunities in our comprehensive Spinal Muscular Atrophy pipeline report @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Spinal Muscular Atrophy Companies

There are approximately 18+ key companies developing therapies for Spinal Muscular Atrophy, with Scholar Rock having the most advanced drug candidate in Phase III. The companies listed in the report include:

• Scholar Rock
• Biogen
• Astellas Pharma
• Alcyone Therapeutics
• AndroScience Corporation
• Hanugen Theraputics
• Voyager Therapeutics
• Hoffmann-La Roche
• Catalyst Pharmaceuticals
• NMD Pharma
• Biohaven Pharmaceuticals
• CANbridge Pharmaceuticals Inc.
• Aurimed Pharma
• Exicure
• Amylon Therapeutics
• Amniotics, and others.

Spinal Muscular Atrophy Clinical Trial Phases

DelveInsight's report covers around 20+ products under different phases of clinical development, including:

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and discovery-stage candidates
• Discontinued and inactive candidates

DelveInsight's SMA pipeline report provides therapeutic assessment of pipeline drugs by route of administration. The products are categorized under:

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Spinal Muscular Atrophy products have also been categorized by molecule type, including:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Spinal Muscular Atrophy treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Spinal Muscular Atrophy Pipeline Report

• Coverage: Global.
• Spinal Muscular Atrophy companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, and Amniotics.
• Spinal Muscular Atrophy therapies: Apitegromab, ACTX-401, and other pipeline products highlighted in the report.
• Spinal Muscular Atrophy therapeutic assessment by product type: Mono, Combination, Mono/Combination.
• Spinal Muscular Atrophy therapeutic assessment by clinical stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a healthcare-focused market research and consulting firm that provides high-quality market intelligence and analysis to support informed business decisions. With experienced industry experts and strong life sciences and healthcare expertise, the company offers customized research solutions and insights to clients across the globe.

This release was published on openPR.